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ABSTRACT 
A novel series of 1,3,5-trisubstituted-2-pyrazolines (5a-5t) was prepared via Claisen Schmidt condensation, fol-
lowed by heterocyclization with hydrazine hydrate, substitution of N1 hydrogen of 2-pyrazoline nucleus with 4-
chlorobenzenesulfonylchloride, applying conventional and green chemistry approaches. Among the two, micro-
wave assisted organic synthesis (MAOS) emerged as a better synthetic tool in terms of faster reaction rate and 
high yield. Various physicochemical and spectral studies were conducted to characterize the synthesized deriva-
tives including- IR, Mass, 1H-NMR, 13C-NMR and elemental analysis. During pharmacological evaluation, 
compound 5b showed excellent anti-anxiety activity and compound 5k exhibited the best antidepressant effect at 
the tested doses, 50 and 100 mg/kg b.w., being comparable to diazepam and imipramine, respectively. The dock-
ing experiments confirmed the probable mechanism of neuropharmacological action, showing excellent affinity 
towards MAO-A target protein, which was also evidenced from some of the key interactions with binding site 
residues Ala68, Tyr69 and Phe352. Furthermore, complimentary in silico pharmacokinetic recital without any 
potential risk of neurotoxicity (as evaluated by rotarod and actophotometer tests), or carcinogenicity, mutagenici-
ty, reproductive toxicity, acute toxicity and irritancy (as predicted by LAZAR and OSIRIS programs) signified 
their probable use in depression and anxiety disorders.  
 
Keywords: 2-Pyrazolines, antidepressant and anti-anxiety, neurotoxicity, microwave synthesis, molecular dock-
ing, in silico ADME prediction 
 
 
INTRODUCTION 
Monoamine oxidase (MAO) regulates 
monoaminergic homeostasis and neuro-
transmission in the nervous system. Low 
level of certain neurotransmitters (NTs) in 
the brain, like dopamine (DA), norepineph-
rine (NE), serotonin (5-HT), and gamma 
amino butyric acid (GABA), is the main 
cause of depressive mental disorders. These 
NTs are released during neurotransmission 
and are degraded by the MAOs enzymes. 
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Monoamine oxidase inhibitors (MAOIs) 
block the action of MAOs, and thus increase 
the concentration of NTs in the brain (Mito-
ma and Ito, 1992; Meyer et al., 2006). The 
antidepressant effect of a hydrazine based 
anti-tubercular drug, iproniazid (a structural 
analog of isoniazid) started the journey of 
development of MAOIs. This discovery 
showed the way to design and produce some 
more effective analogs such as phenelzine 
(Zeller and Barsky, 1952). MAOIs belong to 
the first generation antidepressants used for 
decades to treat the patients suffering from 
high level of anxiety, atypical depression 
(Pletscher, 1991), anergic bipolar depression 
and treatment resistant depression (Thase, 
2012), specific phobias, post-traumatic stress 
disorder and migraine headaches resistant to 
other therapies (Gareri et al., 2000). Two 
major therapeutic categories of MAOI: the 
MAO-A inhibitors in certain mental disor-
ders such as depression and anxiety (Amrein 
et al., 1999) and MAO-B inhibitors proved 
their remedial value in neurodegenerative 
diseases (Youdim et al., 2006; Foley et al., 
2000) including Parkinson’s (Cesura and 
Pletscher, 1992) and Alzheimer’s (Volz and 
Gleiter, 1998). The initial hydrazine class of 
MAO inhibitors was associated with some 
severe adverse effects such as liver toxicity 
and cheese reaction (Brown et al., 1989). 
These side-effects were correlated to nonse-
lective and irreversible MAO inhibition. 
These findings prompted research to develop 
selective and reversible type of MAO (A and 
B) inhibitors. Pyrazoline derivatives have at-
tracted substantial attention for years, chiefly 
1,3,5-trisubstituted-2-pyrazoline pharmaco-
phore is allied with encouraging neurological 
activities such as tranquilizer, anticonvulsant 
and antidepressant (Kaplancikli et al., 2010; 
Ozdemir et al., 2008; Palaska et al., 2001; 
Rajendra Prasad et al., 2005; Ruhoglu et al., 
2005), psychoanaleptic, MAO inhibitory and 
other biological activities (Chimenti et al., 
2004; 2010; Gokhan et al., 2003; Gokhan-
Kelekci et al., 2009; Jagrat et al., 2011; Ja-
yaprakash et al., 2008; Karuppasamy et al., 
2010; Maccioni et al., 2010; Manna et al., 
2002; Mishra and Sasmal, 2011; Sahoo et al., 
2010; Agrawal et al., 2012; Gautam et al., 
2010). Considering these facts, some 1,3,5-
trisubstituted-2-pyrazolines were synthesized 
by integrating some novel aromatic and het-
ero-aromatic substitutions at 3rd and 5th posi-
tions, respectively. Microwave facilitated 
synthetic technique was also utilized to pre-
pare the proposed compounds and the results 
were compared to that of the conventional 
heating methods (Lidstrom et al., 2001). This 
work is in continuation to the previous 
communications by our group (Tripathi et 
al., 2016, Upadhyay et al., 2017; Bhandari et 
al., 2013) with some novel derivatives hav-
ing promising potential in the field. 
 
MATERIALS AND METHODS 
S. D. Fine Chemicals and Sigma Aldrich, 
Mumbai, India supplied the chemicals and 
reagents for synthesis and the pre-coated 
TLC sheets were obtained from Merck 
Chemicals, India and were used as such. Mi-
crowave assisted organic synthesis (MAOS) 
was performed on Raga's Scientific Micro-
wave System (Ragatech, Pune, Maharashtra, 
India).  
 
Chemistry 
The reaction of suitably substituted aro-
matic/heteroaromatic ketones with different 
aldehydes, in alkaline medium, yielded sub-
stituted chalcones (1a-1t) via Claisen-
Schmidt condensation. Then, the formed 
chalcones were reacted with hydrazine hy-
drate (in excess) to give 2-pyrazoline deriva-
tives (2a-2t). Finally, the N1 hydrogen of the 
2-pyrazoline nucleus was replaced with 4-
chlorobenzenesulfonylchloride (5a-5t), as 
given in Figure 1. The reaction progress was 
examined by thin layer chromatography 
(TLC), using pre-coated silica gel G plates as 
stationary phase and iodine vapors/UV light 
as the visualizing agents. 
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Figure 1: Synthesis of 1,3,5-Trisubstituted-2-pyrazoline derivatives 
 
 
Synthesis of chalcone derivatives (1a-1t) 
The proposed chalcone derivatives of the 
first step were synthesized by reacting suita-
bly substituted aldehydes and ketones, in 
equimolar ratio, via conventional and mi-
crowave assisted organic synthesis (MAOS) 
procedures (Tripathi et al., 2016; Upadhyay 
et al., 2017; Agrawal et al., 2012; Gautam et 
al., 2010).  
Synthesis of 3,5-disubstituted-2-pyrazoline 
derivatives(2a-2t) 
The 3,5-disubstituted-2-pyrazoline deriv-
atives of the second step were synthesized by 
reacting different chalcone derivatives of the 
first step with hydrazine hydrate (excess), 
using conventional and MAOS procedures 
(Tripathi et al., 2016; Upadhyay et al., 2017). 
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Synthesis of 1,3,5-trisubstituted-2-
pyrazoline derivatives (5a-5t) 
Conventional synthesis: Appropriately 
substituted 2-pyrazoline derivatives 
(0.001M) of the second step reacted with 4-
chlorobenzenesulfonylchloride (0.002M) by 
stirring, using THF (10 mL) as the solvent. 
Continued the stirring for 1-4 hrs, poured the 
reaction mixture in a petri plate and evapo-
rated the solvent up to dryness. Re-
precipitated the crude product using acetoni-
trile/methanol and re-crystallized from ace-
tonitrile/methanol to obtain the pure product 
(Upadhyay et al., 2017).  
MAOS: Appropriately substituted 3,5-
disubstituted-2-pyrazolines (0.001M) were 
reacted with 4-chlorobenzenesulfonyl-
chloride (0.002M) under microwave irradia-
tion (MWI: 210-350W; 80-280s), taking 
THF (10 mL) as the solvent. The reaction 
mixture was poured in a petri plate and 
evaporated the solvent up to dryness. The 
crude product was re-precipitated using ace-
tonitrile/methanol and recrystallized from 
acetonitrile/methanol to get the purified de-
rivative (Upadhyay et al., 2017). 
 
Characterization of the synthesized 1,3,5-
trisubstituted-2-pyrazoline derivatives 
First and second step intermediate com-
pounds were characterized by TLC, melting 
point (determined by open capillary method 
and are uncorrected) and mass spectrometric 
techniques. However, comprehensive physi-
cochemical (Table 1) and spectral characteri-
zation was undertaken for the final deriva-
tives and the values were found to be in 
agreement.  
4-[1-(4-Chloro-benzenesulfonyl)-5-(3,4-
dimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-
3-yl]-phenol (5a) 
IR spectra were recorded on Bruker FT-
IR, ALPHA-T (Eco-ATR) spectrophotome-
ters, (Bruker Corporation., USA) and the 
values are expressed in cm-1. 3220 (N-H 
stretch), 2865 (C-H Aromatic), 1650 (C=N 
stretch), 1515 (C-H deform), 1159, 1350 
(sym., asym S(=O)2 stretch). 1H-NMR and 
13C-NMR spectra were recorded on Bruker 
Avance-400, FTNMR spectrometer (Bruker, 
Tech. Pvt. Ltd., USA) at 400MHz and the 
chemical shifts are reported in parts per mil-
lion (δ value), taking TMS (δ 0 ppm for 1H 
NMR) as the internal standard: 2.03-2.09 
(dd, Jab: 16.77 Hz, Jax: 3.58 Hz, 1H, Ha), 
2.73-2.78 (dd, Jab: 3.85 Hz, Jbx: 17.11 Hz, 
1H, Hb), 3.81-3.93 (dd, Jax: 3.50 Hz, Jbx: 
17.05 Hz, 1H, Hx), 3.97-4.10 (m, 6H, me-
thyl), 5.23-5.25 (s, 1H, Ar-OH), 6.56-7.90 
(m, 11H, Ar). 13C NMR (DMSO, ppm): 37.9 
(CH2 pyrazoline), 43.0 (CH pyrazoline), 
113.8-146.3 (12CH benzene), 147.5-159.2 
(7C benzene), 160.1 (C pyrazoline). Mass 
spectra were recorded on Waters UPLC-
TQD Mass Spectrometer instrument (Waters 
Corporation, USA) using LC-ESI or APCI-
MS Technique; MS (m/z): 473 (M+, 100 %). 
Elemental analysis was performed on Perkin 
Elmer-2400, Series-II Analyzer (Waltham, 
Massachusetts, USA). Anal. Calcd. for 
C23H21ClN2O5S: C, 58.41; H, 4.48; N, 5.92. 
Found: C, 58.39; H, 4.50; N, 5.89.  
4-[1-(4-Chloro-benzenesulfonyl)-5-(4-
chloro-phenyl)-4,5-dihydro-1H-pyrazol-3-
yl]-phenol (5b) 
IR (cm-1): 3359 (N-H stretch), 3142 (C-H 
Aromatic), 1606 (C=N stretch), 1516 (C-H 
deform), 1165, 1351 (sym., asym S(=O)2 
stretch). 1H-NMR ( δ ppm, DMSO): 1.98-
1.99 (dd, Jab: 17.12 Hz, Jax: 3.41 Hz, 1H, 
Ha), 3.40-3.48 (dd, Jab: 4.01 Hz, Jbx: 16.23 
Hz, 1H, Hb), 3.70-3.80 (dd, Jax: 3.28 Hz, Jbx: 
17.46 Hz, 1H, Hx), 5.39-5.45 (s, 1H, Ar-
OH), 6.88-7.89 (m, 12H, Ar). 13C NMR 
(DMSO, ppm): 38.6 (CH2 pyrazoline), 43.2 
(CH pyrazoline), 115.6-140.3 (12CH ben-
zene), 158.3-160.1 (3C benzene), 161.2 (C 
pyrazoline). MS (m/z): 447 (M+, 100 %). 
Anal. Calcd. for C21H16Cl2N2O3S: C, 56.38; 
H, 3.61; N, 6.26. Found: C, 57.42; H, 3.59; 
N, 6.24. 
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Table 1: Comparative study of physicochemical properties of synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives (5a-5t) 
Com-
pounds 
Structure 
 
Molecular 
Formula  
Color and 
State 
 
Solubility 
 
Rf
Value 
Melting 
Range 
(0C) 
Conventional 
Synthesis (Reflux-
ing) 
Microwave Assisted Organic 
Synthesis (MAOS) 
Reaction 
Time (h) 
% 
Yield 
Microwave 
Power (W) 
Reaction 
Time (s) 
% Yield 
5a  
 
N N
HO
OCH3
OCH3
S
O
O
Cl  
C23H21ClN
2O5S 
Cream  
yellow  
colored 
amorphous 
solid 
Acetonitrile, 
acetone, 
DMSO 
 
0.67 206-
208 
2.5 47 210-240 130 66 
5b 
  
N N
HO
Cl
S
O
O
Cl 
C21H16Cl2
N2O3S 
 
Colorless 
crystalline 
solid 
 
Methanol, 
DMSO, 
chloroform, 
acetone 
0.92 198-
200 
2.0 68 210 85 70 
5c 
 
N NHO
O
S
O
O
Cl 
C19H15ClN
2O4S 
 
Light brown 
colored 
amorphous 
solid 
Methanol,  
acetonitrile, 
chloroform, 
acetone, 
DMSO 
0.88 162-
164 
4.5 58 240-280 210 81 
5d 
 
N NHO
S
S
O
O
Cl 
C19H15ClN
2O3S2 
 
Brown col-
ored amor-
phous solid 
Methanol, 
acetonitrile, 
acetone, 
DMSO  
0.75 148-
150 
3.5 57 240-350 200 82 
5f 
 
N NCl
Cl
S
O
O
Cl 
C21H15Cl3
N2O2S 
 
Grey col-
ored amor-
phous solid 
Methanol,  
acetonitrile, 
chloroform, 
acetone, 
DMSO 
0.52 185-
187 
2.0 45 210-240 150 78 
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Com-
pounds 
Structure 
 
Molecular 
Formula  
Color and 
State 
 
Solubility 
 
Rf
Value 
Melting 
Range 
(0C) 
Conventional 
Synthesis (Reflux-
ing) 
Microwave Assisted Organic 
Synthesis (MAOS) 
Reaction 
Time (h) 
% 
Yield 
Microwave 
Power (W) 
Reaction 
Time (s) 
% Yield 
5g 
 
N NCl
O
S
O
O
Cl 
C19H14Cl2N
2O3S 
 
Black col-
ored amor-
phous solid 
 
Acetonitrile, 
acetone, 
DMSO 
 
0.80 120-
122 
4.0 45 240-350 130 86 
5h 
 
N NCl
S
S
O
O
Cl
 
C19H14Cl2N
2O2S2 
 
Yellowish 
brown col-
ored amor-
phous solid 
Acetonitrile, 
acetone, 
DMSO 
 
0.66 193-
195 
2.5 57 280-350 100 70 
5i 
 
N N
OCH3
OCH3
S
O
O
Cl  
C27H23ClN2
O4S 
 
Orange 
brown col-
ored amor-
phous solid 
Methanol, 
acetone, 
DMSO 
0.92 168-
170 
1.0 48 210-280 100 63 
5j 
 
N N
Cl
S
O
O
Cl 
C25H18Cl2N
2O2S 
 
Cream col-
ored amor-
phous solid 
Acetonitrile, 
acetone, 
DMSO 
 
0.58 178-
180 
2.5 51 280 80 85 
5k 
 
N N
O
S
O
O
Cl 
C23H17ClN2
O3S 
 
Black col-
ored amor-
phous solid 
Acetone, 
DMSO, ace-
tonitrile 
 
0.77 218-
220 
3.0 32 210-280 220 86 
EXCLI Journal 2018;17:126-148 – ISSN 1611-2156 
Received: October 10, 2017, accepted: January 15, 2018, published: January 19, 2018 
 
 
132 
Com-
pounds 
Structure 
 
Molecular 
Formula  
Color and 
State 
 
Solubility 
 
Rf
Value 
Melting 
Range 
(0C) 
Conventional 
Synthesis (Reflux-
ing) 
Microwave Assisted Organic 
Synthesis (MAOS) 
Reaction 
Time (h) 
% 
Yield 
Microwave 
Power (W) 
Reaction 
Time (s) 
% Yield 
5l 
 
N N
S
S OO
Cl  
C23H17ClN2
O2S2 
 
Black col-
ored amor-
phous solid 
 
Acetonitrile, 
acetone, 
DMSO 
 
0.64 112-
114 
3.0 97 280-350 180 94 
5q 
 
N NN
OCH3
OCH3
S
O
O
Cl 
C22H20ClN3
O4S 
 
Brown col-
ored amor-
phous solid 
 
Methanol, 
acetonitrile, 
chloroform, 
acetone, 
DMSO 
0.90 180-
182 
2.5 30 280 160 71 
5r 
 
N N
N
Cl
S
O
O
Cl 
C20H15Cl2N
3O2S 
 
Yellowish 
brown col-
ored amor-
phous solid 
Methanol, 
acetonitrile, 
chloroform, 
acetone, 
DMSO 
0.78 116-
118 
2.0 93 210-350 175 68 
5t 
 
N NN
S
S
O
O
Cl 
C18H14ClN3
O2S2 
 
Brown col-
ored amor-
phous solid 
 
Methanol, 
acetonitrile, 
acetone, 
DMSO 
0.60 138-
140 
3.0 48 280-350 260 72 
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4-[1-(4-Chloro-benzenesulfonyl)-5-furan-2-
yl-4,5-dihydro-1H-pyrazol-3-yl]-phenol (5c) 
IR (cm-1): 3472 (N-H stretch), 3239 (C-H 
Aromatic), 1602 (C=N stretch), 1434 (C-H 
deform), 1159, 1348 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 2.14-
2.16 (dd, Jab: 17.00 Hz, Jax: 3.18 Hz, 1H, Ha), 
3.27-3.36 (dd, Jab: 3.88 Hz, Jbx: 16.69 Hz, 
1H, Hb), 3.42-3.84 (dd, Jax: 3.05 Hz, Jbx: 
16.96 Hz, 1H, Hx), 5.20 (s, 1H, Ar-OH), 
6.04-7.66 (m, 11H, Ar). 13C NMR (DMSO, 
ppm): 40.1 (CH2 pyrazoline), 44.5 (CH pyra-
zoline), 104.2-142.9 (11CH Ar), 135.3-158.6 
(4C benzene), 159.0 (C furan), 160.7 (C py-
razoline). MS (m/z): 229 (M+, 100 %). Anal. 
Calcd. for C19H15ClN2O4S: C, 56.65; H, 
3.75; N, 6.95. Found: C, 56.66; H, 3.77; N, 
6.93.  
4-[1-(4-Chloro-benzenesulfonyl)-5-thiophen-
2-yl-4,5-dihydro-1H-pyrazol-3-yl]-phenol 
(5d) 
IR (cm-1): 3270 (N-H stretch), 3010 (C-H 
Aromatic), 1615 (C=N stretch), 1463 (C-H 
deform), 1189, 1382 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 1.99-
2.00 (dd, Jab: 15.72 Hz, Jax: 3.86 Hz, 1H, Ha), 
3.40-3.48 (dd, Jab: 3.94 Hz, Jbx: 16.70 Hz, 
1H, Hb), 3.71-3.85 (dd, Jax: 3.28 Hz, Jbx: 
17.46 Hz, 1H, Hx), 5.45 (s, 1H, Ar-OH), 
6.75-7.80 (m, 11H, Ar). 13C NMR (DMSO, 
ppm): 39.4 (CH2 pyrazoline), 44.8 (CH pyra-
zoline), 113.8-138.6 (11CH Ar), 120.1-151.7 
(4C benzene), 161.3 (C thiophene), 162.4 (C 
pyrazoline). MS (m/z): 419 (M+, 95 %). 
Anal. Calcd. for C19H15ClN2O3S2: C, 54.47; 
H, 3.61; N, 6.69. Found: C, 54.43; H, 3.62; 
N, 6.67. 
1-(4-Chloro-benzenesulfonyl)-3,5-bis-(4-
chloro-phenyl)-4,5-dihydro-1H-pyrazole (5f) 
IR (cm-1): 3315 (N-H stretch), 3100 (C-H 
Aromatic), 1616 (C=N stretch), 1465 (C-H 
deform), sym., asym S(=O)2 stretch (1164, 
1389). 1H NMR (δ ppm, DMSO): 1.91-1.96 
(dd, Jab: 17.56 Hz, Jax: 3.50 Hz, 1H, Ha), 
3.29-3.48 (dd, Jab: 4.01 Hz, Jbx: 17.23 Hz, 
1H, Hb), 3.66-3.84 (dd, Jax: 3.75 Hz, Jbx: 
16.54 Hz, 1H, Hx), 7.00-7.77 (m, 12H, Ar). 
13C NMR (DMSO, ppm): 39.0 (CH2 pyrazo-
line), 42.5 (CH pyrazoline), 125.8-131.2 
(12CH benzene), 136.1-141.9 (4C benzene), 
161.2 (C pyrazoline). MS (m/z): 463 (M+, 
55 %). Anal. Calcd. for C21H15Cl3N2O2S: C, 
54.15; H, 3.25; N, 6.01. Found: C, 54.11; H, 
3.22; N, 6.00.  
1-(4-Chloro-benzenesulfonyl)-3-(4-chloro-
phenyl)-5-furan-2-yl-4,5-dihydro-1H-
pyrazole (5g) 
IR (cm-1): 3330 (N-H stretch), 3092 (C-H 
Aromatic), 1685 (C=N stretch), 1539 (C-H 
deform), 1168, 1355 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 2.08-
2.13 (dd, Jab: 15.31 Hz, Jax: 2.98 Hz, 1H, Ha), 
3.39-3.44 (dd, Jab: 4.16 Hz, Jbx: 15.57 Hz, 
1H, Hb), 3.61-3.79 (dd, Jax: 3.58 Hz, Jbx: 
16.95 Hz, 1H, Hx), 6.53-7.60 (m, 11H, Ar). 
13C NMR (DMSO, ppm): 39.9 (CH2 pyrazo-
line), 42.5 (CH pyrazoline), 107.7-128.5 
(11CH Ar), 130.2-136.8 (3C benzene), 159.0 
(C furan), 161.7 (C pyrazoline). MS (m/z): 
421 (M+, 65 %). Anal. Calcd. for 
C19H14Cl2N2O3S: C, 54.17; H, 3.35; N, 6.65. 
Found: C, 54.20; H, 3.39; N, 6.61.  
1-(4-Chloro-benzenesulfonyl)-3-(4-chloro-
phenyl)-5-thiophen-2-yl-4,5-dihydro-1H-
pyrazole (5h) 
IR (cm-1): 3345 (N-H stretch), 3056 (C-H 
Aromatic), 1621 (C=N stretch), 1471 (C-H 
deform), 1165, 1393 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 2.10-
2.19 (dd, Jab: 16.88 Hz, Jax: 3.29 Hz, 1H, Ha), 
4.15-4.22 (dd, Jab: 4.01 Hz, Jbx: 16.78 Hz, 
1H, Hb), 4.20-4.23 (dd, Jax: 3.63 Hz, Jbx: 
16.91 Hz, 1H, Hx), 6.65-7.79 (m, 11H, Ar). 
13C NMR (DMSO, ppm): 39.7 (CH2 pyrazo-
line), 41.3 (CH pyrazoline), 121.4-136.5 
(11CH Ar), 128.6-134.1 (3C benzene), 139.4 
(C thiophene), 155.8 (C pyrazoline). MS 
(m/z): 437 (M+, 40 %). Anal. Calcd. for 
C19H14Cl2N2O2S2: C, 52.18; H, 3.23; N, 
6.41. Found: C, 52.17; H, 3.20; N, 6.47.  
1-(4-Chloro-benzenesulfonyl)-5-(3,4-
dimethoxy-phenyl)-3-naphthalen-1-yl-4,5-
dihydro-1H-pyrazole (5i) 
IR (cm-1): 3345 (N-H stretch), 3056 (C-H 
Aromatic), 1577 (C=N stretch), 1462 (C-H 
deform), 116570, 1362 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 1.97-
1.98 (dd, Jab: 17.22 Hz, Jax: 3.52 Hz, 1H, Ha), 
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3.39-3.47 (dd, Jab: 3.87 Hz, Jbx: 16.73 Hz, 
1H, Hb), 3.54-3.69 (dd, Jax: 3.18 Hz, Jbx: 
17.26 Hz, 1H, Hx), 3.80-3.94 (m, 6H, me-
thyl), 6.78-7.64 (m, 14H, Ar). 13C NMR 
(DMSO, ppm): 39.7 (CH2 pyrazoline), 42.5 
(CH pyrazoline), 61.7 (2CH3), 113.7-132.5 
(14CH Ar), 130.8-137.2 (7C Ar), 159.3 (C 
pyrazoline). MS (m/z): 507 (M+, 50 %). 
Anal. Calcd. for C27H23ClN2O4S: C, 63.96; 
H, 4.57; N, 5.53. Found: C, 64.07; H, 4.61; 
N, 5.46.  
1-(4-Chloro-benzenesulfonyl)-5-(4-chloro-
phenyl)-3-naphthalen-1-yl-4,5-dihydro-1H-
pyrazole (5j) 
IR (cm-1): 3266 (N-H stretch), 3011 (C-H 
Aromatic), 1570 (C=N stretch), 1495 (C-H 
deform), 1166, 1362 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 2.15-
2.19 (dd, Jab: 16.68 Hz, Jax: 3.27 Hz, 1H, Ha), 
3.83-3.88 (dd, Jab: 3.95 Hz, Jbx: 17.10 Hz, 
1H, Hb), 3.50-3.67 (dd, Jax: 4.12 Hz, Jbx: 
16.97 Hz, 1H, Hx), 6.90-7.73 (m, 14H, Ar). 
13C NMR (DMSO, ppm): 39.2 (CH2 pyrazo-
line), 46.4 (CH pyrazoline), 124.2-129.0 
(14CH Ar), 128.5-136.1 (7C benzene), 158.7 
(C pyrazoline). MS (m/z): 481 (M+, 50 %). 
Anal. Calcd. for C25H18Cl2N2O2S: C, 62.37; 
H, 3.77; N, 5.82. Found: C, 62.49; H, 3.80; 
N, 5.78.  
1-(4-Chloro-benzenesulfonyl)-5-furan-2-yl-
3-naphthalen-1-yl-4,5-dihydro-1H-pyrazole 
(5k) 
IR (cm-1): 3290 (N-H stretch), 3050 (C-H 
Aromatic), 1635 (C=N stretch), 1469 (C-H 
deform), 1166, 1355 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 2.48-
2.51 (dd, Jab: 17.12 Hz, Jax: 3.41 Hz, 1H, Ha), 
3.04-3.89 (dd, Jab: 4.01 Hz, Jbx: 16.23 Hz, 
1H, Hb), 4.88-5.21 (dd, Jax: 3.28 Hz, Jbx: 
17.46 Hz, 1H, Hx), 6.80-6.93 (d, 2H, Ar), 
7.43-7.54 (m, 4H, Ar), 7.66-7.85 (m, 7H, 
Ar). 13C NMR (DMSO, ppm): 50.7 (CH2 py-
razoline), 77.2 (CH pyrazoline), 124.4-126.9 
(2CH furan), 129.0-131.3 (7CH naphtha-
lene), 133.7-138.2 (4CH benzene), 159.4 (C 
pyrazoline). MS (m/z): 437 (M+, 50 %), 438 
(30 %). Anal. Calcd. for C23H17ClN2O3S: C, 
63.23; H, 3.92; N, 6.41. Found: C, 63.26; H, 
3.97; N, 6.40.  
1-(4-Chloro-benzenesulfonyl)-3-naphthalen-
1-yl-5-thiophen-2-yl-4,5-dihydro-1H-
pyrazole (5l) 
IR (cm-1): 3292 (N-H stretch), 3047 (C-H 
Aromatic), 1581 (C=N stretch), 1509 (C-H 
deform), 1177, 1322 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 2.08-
2.09 (dd, Jab: 17.48 Hz, Jax: 2.99 Hz, 1H, Ha), 
3.10-3.18 (dd, Jab: 3.74 Hz, Jbx: 17.04 Hz, 
1H, Hb), 3.83-3.86 (dd, Jax: 3.26 Hz, Jbx: 
16.36 Hz, 1H, Hx), 6.60-7.92 (m, 14H, Ar). 
13C NMR (DMSO, ppm): 40.6 (CH2 pyrazo-
line), 46.1 (CH pyrazoline), 118.5-129.2 
(14CH Ar), 137.8-148.1 (6C Ar), 161.5 (C 
pyrazoline). MS (m/z): 463 (M+, 50 %). 
Anal. Calcd. for C23H17ClN2O2S2: C, 60.98; 
H, 3.78; N, 6.18. Found: C, 61.06; H, 3.76; 
N, 6.21.  
2-[1-(4-Chloro-benzenesulfonyl)-5-(3,4-
dimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-
3-yl]-pyridine (5q) 
IR (cm-1): 3321 (N-H stretch), 3084 (C-H 
Aromatic), 1624 (C=N stretch), 1466 (C-H 
deform), 1170, 1337 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 1.89-
1.91 (dd, Jab: 15.62 Hz, Jax: 3.17 Hz, 1H, Ha), 
3.33-3.39 (dd, Jab: 3.74 Hz, Jbx: 17.11 Hz, 
1H, Hb), 3.65-3.80 (dd, Jax: 3.54 Hz, Jbx: 
16.91 Hz, 1H, Hx), 3.73-3.94 (m, 6H, me-
thyl), 6.97-8.21 (m, 11H, Ar). 13C NMR 
(DMSO, ppm): 40.2 (CH2 pyrazoline), 45.7 
(CH pyrazoline), 49.5 (6C, CH3), 114.9-
135.8 (11CH Ar), 143.4-152.8 (6C benzene), 
161.9 (C pyrazoline). MS (m/z): 458 (M+, 
30 %). Anal. Calcd. for C22H20ClN3O4S: C, 
57.70; H, 4.40; N, 9.18. Found: C, 57.64; H, 
4.45; N, 9.14.  
2-[1-(4-Chloro-benzenesulfonyl)-5-(4-
chloro-phenyl)-4,5-dihydro-1H-pyrazol-3-
yl]-pyridine (5r) 
IR (cm-1): 3421 (N-H stretch), 3091 (C-H 
Aromatic), 1616 (C=N stretch), 1471 (C-H 
deform), 1170,2 1383 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 1.91-
1.94 (dd, Jab: 17.36 Hz, Jax: 3.21 Hz, 1H, Ha), 
3.64-3.48 (dd, Jab: 4.12 Hz, Jbx: 17.44 Hz, 
1H, Hb), 3.69-3.85 (dd, Jax: 3.28 Hz, Jbx: 
16.55 Hz, 1H, Hx), 7.29-8.69 (m, 12H, Ar). 
13C NMR (DMSO, ppm): 40.2 (CH2 pyrazo-
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line), 44.5 (CH pyrazoline), 124.6-149.2 
(12CH Ar), 137.1-139.4 (2C benzene), 154.2 
(C pyridine), 160.7 (C pyrazoline). MS 
(m/z): 432 (M+, 55%). Anal. Calcd. for 
C20H15Cl2N3O2S: C, 55.56; H, 3.50; N, 9.72. 
Found: C, 55.60; H, 3.51; N, 9.68.  
2-[1-(4-Chloro-benzenesulfonyl)-5-thiophen-
2-yl-4,5-dihydro-1H-pyrazol-3-yl]-pyridine 
(5t) 
IR (cm-1): 3387 (N-H stretch), 3083 (C-H 
Aromatic), 1612 (C=N stretch), 1468 (C-H 
deform), 1167, 1389 (sym., asym S(=O)2 
stretch). 1H NMR (δ ppm, DMSO): 1.90-
1.93 (dd, Jab: 17.23 Hz, Jax: 3.32 Hz, 1H, Ha), 
3.46-3.50 (dd, Jab: 3.87 Hz, Jbx: 16.65 Hz, 
1H, Hb), 3.82-3.89 (dd, Jax: 3.14 Hz, Jbx: 
16.91 Hz, 1H, Hx), 6.53-8.97 (m, 11H, Ar). 
13C NMR (DMSO, ppm): 38.6 (CH2 pyrazo-
line), 43.2 (C pyrazoline), 115.6-140.3 
(12CH benzene), 144.9-157.1 (4C Ar), 161.3 
(C pyrazoline). MS (m/z): 403 (M+, 25 %). 
Anal. Calcd. for C18H14ClN3O2S2: C, 53.53; 
H, 3.49; N, 10.40. Found: C, 53.49; H, 3.53; 
N, 10.37.  
 
Biological evaluation 
Study animals 
The study protocols were authenticated 
by the Institutional Animal Ethics Commit-
tee (IAEC) with the protocol number 
BBDNIIT/IAEC/009/2014.  
Animal house, Faculty of Pharmacy, 
BBDNIIT, Lucknow, U.P., India provided 
animals (male albino mice) for the in-vivo 
study which were treated humanely and 
maintained under standard conditions of 
temperature (26 ± 2 ºC), percent humidity 
(55 ± 5), light and dark cycles and free ac-
cess to food and water.  
Study design 
The studies were performed as per re-
ported procedures (Tripathi et al., 2016; 
Upadhyay et al., 2017). The detailed descrip-
tion of the groups and respective doses are 
given in Table 2. 
Antidepressant activity 
The antidepressant potential of the syn-
thesized derivatives (5a-5t) was evaluated 
using behavioral in vivo tests in mice model, 
such as forced swim test (FST) and tail sus-
pension test, (TST) as given by Porsolt 
(1981) and Willner and Mitchell (2002). 
- Porsolt’s behavioral despair or FST  
In FST, the state of despair can be mini-
mized by different therapeutically effective 
antidepressants (Porsolt et al., 1977; Vogel, 
2002). The duration of immobility in ani-
mals, produced by the test compounds, was 
measured by known procedures (Tripathi et 
al., 2016; Upadhyay et al., 2017). 
- Tail suspension test (TST)  
TST is another well known method (Ste-
ru et al., 1985; Vogel, 2002), employed to 
evaluate the antidepressant potential of the 
test compounds. In this test, the duration of 
immobility was measured by known proce-
dures (Tripathi et al., 2016; Upadhyay et al., 
2017). 
 
Anti-anxiety activity 
The maze model was used to evaluate an-
ti-anxiety potential of the test compounds, 
which selectively identified the anxiolytic 
(open arm exploration time increased and 
time spent in closed arms decreased) and 
anxiogenic drugs (Vogel, 2002). 
Elevated plus-maze test 
The elevated plus-maze was used to de-
termine anxiety-related behavior, measured 
by the extent to which the mouse avoids vis-
iting the open arm of the maze (Lister, 1987; 
Pellow et al., 1985). After one hour of oral 
administration of the test compound, obser-
vations (i.e. time spent in closed arm and to-
tal number of the arm entries) were recorded 
during the 6 minute test duration by known 
procedures (Tripathi et al., 2016; Upadhyay 
et al., 2017). 
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Table 2: Data showing antidepressant, anti-anxiety and neurotoxicity studies of the synthesized 2-pyrazoline derivatives (5a-5t) 
Compounds Group 
Number 
Doses 
(mg/kg 
b.w.) 
Antidepressant Activitya Anti-anxiety Activityb Neurotoxicity Studies
Rotarod Testc Actophotometer Testd 
(Mean Counts) 
Duration of Im-
mobility in FST 
(sec) (Mean±SD) 
Duration of Im-
mobility in TST 
(sec) (Mean±SD) 
Number of En-
tries in Closed 
Arms 
(Mean±SD) 
Time  Spent in 
Closed Arms 
(sec) 
(Mean±SD) 
Before 
Dose 
After 
Dose 
(After 
1h) 
Before 
Dose 
After Dose (Af-
ter 1h) 
5a 
1  50 125.17±8.93 177.83±17.27 10.83±3.66 162.00±21.54 0/6 0/6 291.83 298.00 
2  100 89.50±11.11 174.00±19.97 14.00±2.53 126.33±11.50 1/6 0/6 277.33 284.50 
5b 
3  50 79.33±12.39 107.67±27.44 12.33±2.58 143.83±11.67 0/6 2/6 284.17 284.17 
4  100 85.50±10.50 101.67±15.71 15.67±2.94 102.83±9.58 0/6 0/6 317.17 317.17 
5c 
5  50 82.67±6.41 136.50±18.29 6.83±1.47 194.33±13.59 0/6 0/6 440.17 430.67 
6  100 68.50±15.73 122.83±10.03 7.67±2.94 188.33±15.68 0/6 0/6 275.50 277.67 
5d 
7  50 124.33±9.71 201.17±12.54 8.83±3.06 146.00±14.21 1/6 1/6 446.67 473.33 
8  100 97.67±14.19 155.33±9.73 9.33±4.18 138.67±11.94 0/6 0/6 277.33 272.33 
5f 
9  50 105.17±13.85 97.50±30.25 5.17±2.32 196.33±13.43 0/6 0/6 470.33 461.17 
10  100 87.83±18.79 76.50±20.69 6.50±1.87 211.83±15.25 0/6 1/6 286.17 283.50 
5g 
11  50 104.17±15.56 149.67±8.45 6.50±1.05 273.17±12.58 0/6 0/6 275.50 270.83 
12  100 99.50±14.64 150.50±8.31 9.00±2.37 275.17±26.50 0/6 0/6 284.17 258.33 
5h 
13  50 155.00±11.64 93.00±11.17 3.67±1.63 198.50±19.38 0/6 0/6 477.83 517.50 
14  100 101.67±12.26 149.17±42.10 5.17±2.32 255.67±28.39 0/6 0/6 286.17 301.00 
5i 
15  50 94.33±14.18 133.33±23.85 6.50±3.27 253.17±15.18 0/6 0/6 446.67 445.67 
16  100 73.33±25.40 107.67±17.96 8.67±3.27 208.17±24.26 0/6 0/6 298.00 297.00 
5j 
17  50 112.50±19.15 129.50±37.25 8.00±2.28 222.17±16.80 0/6 0/6 486.67 488.67 
18  100 84.67±13.34 132.17±11.32 9.50±1.87 193.67±20.22 0/6 0/6 286.17 281.83 
5k 
19  50 58.00±7.97 65.83±13.79 7.00±1.79 205.17±14.02 0/6 0/6 485.50 482.67 
20  100 23.00±6.20 37.83±10.25 8.83±2.04 175.17±24.00 0/6 0/6 286.17 282.83 
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Compounds Group 
Number 
Doses 
(mg/kg 
b.w.) 
Antidepressant Activitya Anti-anxiety Activityb Neurotoxicity Studies
Rotarod Testc Actophotometer Testd 
(Mean Counts) 
Duration of Im-
mobility in FST 
(sec) (Mean±SD) 
Duration of Im-
mobility in TST 
(sec) (Mean±SD) 
Number of En-
tries in Closed 
Arms 
(Mean±SD) 
Time  Spent in 
Closed Arms 
(sec) 
(Mean±SD) 
Before 
Dose 
After 
Dose 
(After 
1h) 
Before 
Dose 
After Dose (Af-
ter 1h) 
5l 
21  50 59.67±9.93 129.17±17.93 7.67±3.20 164.83±14.74 1/6 1/6 275.50 269.33 
22  100 43.50±8.04 54.83±15.88 9.17±2.32 137.83±10.46 0/6 0/6 284.17 282.50 
5q 
23  50 73.00±17.13 107.50±17.90 8.83±2.32 214.17±15.22 0/6 0/6 286.17 288.33 
24  100 70.50±16.96 76.67±6.59 12.50±2.07 170.33±18.00 0/6 1/6 275.50 274.67 
5r 
25  50 158.33±9.07 114.50±13.13 2.50±2.43 225.17±22.44 0/6 0/6 284.17 279.17 
26  100 103.83±10.11 100.83±11.75 4.00±3.03 233.33±22.65 0/6 0/6 279.17 276.00 
5t 
27  50 107.50±8.87 101.17±14.97 7.33±2.25 274.17±19.03 0/6 0/6 281.67 272.83 
28  100 79.67±11.48 76.67±6.59 8.50±2.81 257.67±34.37 0/6 0/6 277.33 287.00 
Control 
(CMC) 29  0.5% 179.67± 18.67 219.00±17.56 0.83±0.75 281.67±41.09 0/6 0/6 410.33 394.17 
Standard 
drug 
(Imipramine) 
30  10 
 
29.33±8.43 
 
 
60.33±9.33 
 
 
--- 
 
 
--- 
 
0/6 1/6 
 
399.50 
 
404.83 
Standard 
drug 
( Diazepam) 
31  2 --- --- 9.33±3.08 177.33±45.18 0/6 0/6 
 
228.00 
 
239.67 
Bold data represents the most active compounds in the series. 
n=6 (Number of animals tested at each dose level); p < 0.05. 
Control: Carboxy methyl cellulose (CMC, 0.5 % suspension).  
Standard: Imipramine (10 mg/kg, b.w.) for antidepressant activity and Diazepam (2 mg/kg, b.w.) for anti-anxiety activity. 
a The reduction in time of immobility in FST and TST are an established way to evaluate effectiveness of antidepressants.  
b The number of entries is increased in anxiolytic agents and decrease in anxiogenic agents and the amount of time spent in closed arms is  
decreased in anxiolytic agents and increase in anxiogenic agents.  
c Neurotoxicity was evaluated in Rotarod test before dosing and after 1 hour of dosing (number of animals exhibiting toxicity/number of animals tested).  
d Neurotoxicity recorded in actophotometer test (Counts recorded in 10 minutes duration) 
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Neurotoxicity study  
This study was used to evaluate the effect 
of the compounds on the CNS, employing 
various behavioral tests, such as rotarod, 
open-field/actophotometer, turning on flat 
surface and inclined plane tests in mice 
model (Vogel, 2002; Parasuraman, 2011). 
 
Neuromuscular coordination study 
The effect of the compounds on motor 
coordination, where relaxation of skeletal 
muscle is produced, was examined, as per 
method given by Dunham and Miya in 1957, 
with slight modification (Vogel et al., 2002).  
Locomotor activity (actophotometer test) 
Locomotor activities of the animals were 
used as an index of their mental alertness, 
which is affected (increased or decreased) by 
majority of the CNS acting drugs (Dhingra 
and Goyal, 2008; Tripathi et al., 2016; 
Upadhyay et al., 2017). 
 
Acute toxicity study 
The consequences (changes in skin and 
fur, behavior patterns, convulsions, tremors 
and death) of a single dose on a particular 
animal species was determined by acute tox-
icity testing. In this study, acute oral toxicity 
(LD50) of two most active final derivatives 
(5b and 5k) was performed as per guidelines 
laid by Organization for Economic Coopera-
tion and Development (OECD) guideline No 
423 “Acute Oral Toxicity - Acute Toxic 
Class Method” using known procedures 
(OECD, 2001). 
 
Computational studies 
Molecular docking simulations were 
used to predict binding affinity and binding 
orientations of the synthesized compounds to 
the MAO-A protein (PDB ID: 2Z5X), with 
the help of GLIDE program (Schrödinger, 
LLC, 2014), using known procedures (Tripa-
thi et al., 2016; Upadhyay et al., 2017). 
QikProp module of Schrödinger software 
program was successfully employed for in 
silico prediction of ADME properties of the 
synthesized derivatives. Furthermore, for in 
silico toxicity prediction of the synthesized 
compounds, two freely accessible computer 
programs (LAZAR and OSIRIS Property 
explorer) were employed. Among them, 
LAZAR provided a generic tool for predict-
ing complex toxicological end points (like 
long-term toxicity, reproductive toxicity and 
carcinogenicity). OSIRIS program calculated 
various drug-related properties of chemical 
structures and risks of untoward effects, 
which are considered as an indication of 
drug-conform behavior (Klebe, 2000). 
 
Statistical analysis 
Statistical analysis was carried out using 
Graph Pad Prism 5.0 (Graph Pad Software, 
San Diego, CA). Experimental results are 
expressed as mean±SD, analyzed by one-
way ANOVA followed by Dunnett’s test for 
the possible significance (P<0.05) between 
various groups.  
 
RESULTS AND DISCUSSION 
A total of fourteen 1,3,5-trisubstituted 2-
pyrazoline derivatives (5a-5t) were prepared 
through Claisen-Schmidt condensation, fol-
lowed by heterocyclization and substitution 
with 4-chlorobenzenesulfonylchloride using 
both, conventional and MAOS methods. The 
microwave assisted procedures were devel-
oped for the first time to synthesize the final 
1,3,5-trisubstituted-2-pyrazoline derivatives. 
The research outcomes suggested that almost 
all the derivatives synthesized by this tech-
nique were obtained at a faster rate and in a 
better synthetic yield in comparison to con-
ventional procedures. The prepared deriva-
tives were analyzed by various physico-
chemical (Table 1) and spectral techniques 
and results comply with the proposal. The IR 
spectra reflect some characteristic absorption 
bands in the corresponding regions to C=N 
str (1509-1612 cm-1), N-H str (3449-3107 
cm-1) and C-H deform (1431-1354 cm-1). In 
the third step derivatives, a characteristic 
peak of sulfonyl group was also observed in 
the IR spectra. 1H-NMR spectra showed that 
two dissimilar methylene protons (Ha/Hb) 
were visible at δ 2.92–3.38 ppm, 3.70–3.93 
which coupled themselves and with the me-
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thine proton (Hx) at δ 6.67–7.03 in vicinity. 
The other values were in congruence with 
the corresponding aliphatic and aromatic 
protons. 
The pharmacological results (Table 2 and 
Figure 2) demonstrated that number of en-
tries in closed and open arms, in the elevated 
plus maze test, increased significantly with a 
lesser closed arm exploration time (Figure 2a 
and 2b) for Compound 5b and Compound 5k 
showed the best antidepressant action (Fig-
ure 2c and 2d) in FST and TST models at the 
evaluated doses. The pharmacological ac-
tions of the prepared analogs were observed 
in a dose dependent manner, as the magni-
tude of the effects increased at higher tested 
doses (100 mg/kg b.w.). The structure activi-
ty relationship studies established that C-3 
naphthalen-1-yl substitution and C-5 furan-
2-yl substitution at 2-pyrazoline nucleus 
were crucial for the antidepressant activity 
(5k). However, a polar substitution of 4-
hydroxyphenyl group at 3rd position (5b) was 
essential in eliciting anxiolytic activity.
 
 
Figure 2: (a) Anti-anxiety activity (Number of entries in closed arms in Elevated Plus Maze Test);  
(b) Anti-anxiety activity (Time spent in closed arms in Elevated Plus Maze Test). 
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Figure 2 (cont.): (c) Antidepressant activity (Forced Swim Test); (d) Antidepressant activity (Tail Sus-
pension Test) 
 
 
MAOs are considered as an important 
biological target to develop drugs against 
certain mental disorders, such as depression 
and anxiety.  It has been also established that 
the 2-pyrazoline derivatives possess excel-
lent affinity towards MAO isoforms, as re-
ported in previous literatures. Docking stud-
ies allowed to gain some structural inputs 
towards binding characteristics of the pre-
pared derivatives with the MAO-A target 
protein. The most stable conformation of lig-
and-protein complex and the interaction 
studies of the most active compounds, 5b 
and 5k at the MAO-A protein binding pocket 
have been depicted in Figure 3 and 4. Dock-
ing studies inferred that Ala 68, Tyr69 and 
Phe352 are some important residues interact-
ing at the MAO-A binding pocket. It was ev-
ident that at 2-pyrazoline nucleus, N1 p-
chlorobenzenesulfonyl substitution proved to 
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be very useful and all the compounds having 
this substitution showed better activity than 
the N1 unsubstituted pyrazolines (Tripathi et 
al., 2016). The presence of sulfonyl group at 
N1 position of 2-pyrazoline nucleus evi-
denced H-bonding interaction between sul-
fonyl oxygen and Ala68 and Tyr69 residues 
at the MAO-A binding pocket. It was 
demonstrated in previous works that ligands 
having such type of hydrogen bond interac-
tions are well placed in the aromatic cage of 
the MAO protein possessing C5 furyl/ sub-
stituted phenyl ring and N1-benzenesulfonyl 
ring of 2-pyrazoline nucleus. The naph-
thyl/4-chlorophenyl rings showed, impera-
tive pi-pi stacking interactions with Phe352 
backbone residue. It was also evident that 
most of the interactions of PDB co-crystal 
ligand 2Z5X were conserved in compounds 
5b and 5k. Furthermore, the predicted bind-
ing affinity (Glide gscores) of the prepared 
analogs complemented well with the in vivo 
anti-anxiety and antidepressant activities da-
ta. 
The synthesized compounds were also 
tested for their probable neurotoxicological 
effects, such as motor coordination (rotarod 
test) and locomotor activity (actophotometer 
test). The obtained results suggested that 
these derivatives were completely free from 
severe neurotoxicity (motor co-ordinations 
and locomotor disturbances) threats at the 
evaluated doses (Table 2). In Rotarod test, 
the mean fall-off time of most of the mice 
was greater than 180 seconds, and hence 
these compounds may not affect the motor 
coordination of the animals. Also, the mean 
counts in actophotometer test in pre-dose 
studies, and after 1 hour of dosing, were not 
significantly different and therefore, any 
probability of CNS stimulating or depressing 
effects of the tested compounds was ruled 
out. Additionally, most potent derivatives 
were evaluated for their acute toxicity at the 
corresponding doses. None of them showed 
any changes in behavioral pattern, convul-
sions, tremors, skin changes and death 
throughout the 14 days acute toxicity studies. 
Also, encouraging in silico pharmacokinetic 
properties (Table 3) were observed. Moreo-
ver, the screened compounds were not liable 
to cause carcinogenicity, mutagenicity, re-
productive toxicity, acute toxicity and irri-
tancy. Therefore, they were regarded to be 
safe as was corroborated by the computa-
tional programs such as LAZAR and OSIRIS 
(Table 4). 
 
CONCLUSION 
This study concludes that the synthesized 
2-pyrazoline analogs possess excellent to 
good antidepressant and anti-anxiety poten-
tial, as evaluated using various in vivo meth-
ods.  The presence of C-3 naphthalen-1-yl 
substitution and C-5 furan-2-yl substitution 
at 2-pyrazoline nucleus was decisive for the 
antidepressant activity (5k). However, a po-
lar substitution of 4-hydroxyphenyl group at 
3rd position (5b) was essential in eliciting 
anxiolytic activity. Nearly all the compounds 
were completely free from any neurotoxic 
indications, with a complementary pharma-
cokinetic behavior as predicted by in silico 
methods. Molecular docking experiments as-
certained some imperative interactions of 
these compounds with the target protein, 
playing a pivotal role in neuropharmacology. 
Thus, in a nutshell, the synthesized 2-
pyrazoline derivatives may prove their worth 
in the treatment and management of certain 
mental disorders, possibly through MAO-A 
inhibition.  
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Figure 3: Ligand receptor interaction diagram of compound 5b at the binding site of MAO-A protein 
(PDB ID: 2Z5X) showing best anti-anxiety activity. (a) 2D Ligand receptor interaction diagram. (b) 3D 
Ligand receptor interaction diagram. 
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Figure 4: Ligand receptor interaction diagram of compound 5k at the binding site of MAO-A protein 
(PDB ID: 2Z5X) showing best antidepressant activity. (a) 2D Ligand receptor interaction diagram. (b) 
3D Ligand receptor interaction diagram. 
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Table 3: In silico prediction of binding affinity (Glide gscore) and ADME parameters of the synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives (5a-5t) 
Com-
pounds 
Glide 
gscore 
#Sta
rs 
MW Volume PSA SASA Donar-
HB 
Ac-
cptH
B 
CNS QPlog
BB 
QlogP
o/w 
QPlog
Khsa 
QPP
Caco 
Site of
metab 
% 
Human 
Oral 
absorp-
tion 
Viola-
tions of 
Rule of 
Five 
5a -7.36 0 472.94 1272.98 86.63 666.85 1 7.75 -1 -0.80 3.70 0.35 582.26 5 100 0 
5b -8.91 0 447.34 1184.44 73.71 639.41 1 6.25 0 -0.53 4.08 0.50 557.41 3 100 0 
5c -8.75 0 402.85 1094.53 82.24 602.32 1 6.75 0 -0.68 3.09 0.16 520.10 4 93.64 0 
5d -8.10 0 418.91 1130.25 74.61 622.66 1 6.25 0 -0.60 3.65 0.35 538.82 4 100 0 
5f -7.73 1 465.78 1205.86 51.17 651.08 0 5.50 1 0.20 5.09 0.56 1836.33 2 100 1 
5g -8.82 0 421.30 1115.91 59.71 613.96 0 6.00 1 0.05 4.04 0.17 1713.80 3 100 0 
5h -7.80 1 437.36 1151.77 52.08 634.43 0 5.50 1 0.14 4.66 0.41 1775.53 3 100 0 
5i -8.78 0 507.00 1389.36 64.30 720.45 0 7.00 0 -0.21 5.16 0.61 2166.91 4 90.92 2 
5j -9.06 1 481.40 1294.00 51.34 690.76 0 5.50 1 0.078 5.579 0.82 2146.71 2 100 1 
5k -9.24 1 436.91 1204.01 59.87 652.93 0 6.00 0 -0.09 4.52 0.42 1972.42 3 100 0 
5l -8.36 0 452.97 1240.41 52.23 673.58 0 5.50 1 0.01 5.14 0.66 2055.46 3 100 1 
5q -7.20 0 457.93 1240.78 76.47 652.37 0 8.00 -1 -0.36 3.46 -0.09 1384.40 5 100 0 
5r -8.59 0 432.32 1152.67 63.55 624.66 0 6.50 0 -0.10 3.92 0.14 1315.15 3 100 0 
5t -8.12 0 403.90 1099.01 64.46 608.64 0 6.50 0 -0.17 3.48 -0.02 1263.71 4 100 0 
2Z5X -6.89 0 212.25 733.39 33.50 381.35 1 1.75 0 0.18 3.11 0.222 840.62 3 100 0 
Std. 
values 
--- 0-5 130 to 
725 
500 to 
2000 
7 to 
200 
300 to 
1000 
0 to 6 2 to 
20 
-2 to 
+2 
-3.0 
to 1.2 
 
-2.0 
to 6.5 
-1.5 
to 1.5 
<25poor 
>500 
great 
1 to 8 <20% 
low, 
>80% 
high 
Maxi-
mum is 
4 
 
#stars: Number of property or descriptor values that fall outside the 95 % range of similar values for known drugs; Volume: Total solvent accessible volume in 
cubic angstrom using a probe with 1.4 Ǻ radius; PSA: Van der Waals polar surface area of nitrogen and oxygen atoms; SASA: Total solvent accessible surface 
area in sqare angstrom using a probe with 1.4 Ǻ radius; donarHB: Hydrogen bond donar; accptHB: Hydrogen bond acceptor; CNS: Predicted central nervous 
system activity at -2 (inactive) to +2 (active) scale; QPlogBB: Predicted brain/blood partition coefficient; QlogPo/w: Predicted octanol-water partition coefficient. 
QPlogKhsa: Prediction of binding to human serum albumin; QPPCaco: Predicted apparent Caco-2 cell permeability in nm/sec; metab: Number of likely meta-
bolic reactions; Number of violations of Lipinski’s rule of five. 
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Table 4: In silico toxicity prediction data of the synthesized 1,3,5-trisubstituted -2-pyrazoline derivatives (5a-5t) 
Compounds Toxicity prediction 
OSIRIS PROPERTY EXPLORER LAZAR 
Mutagenic Tumorigenic Irritant Reproductive 
effect 
Maximum rec-
ommended 
daily dose 
(mmol) 
Mutagenicity Acute toxicity 
LC50 (mmol) 
Carcinogenic 
potency 
5a  - - - - 4.23e+00 - 5.51e+00 - 
5b - - - - 4.62e+00 - 1.38e+01 - 
5c - - - - 1.44e+01 - 2.31e+01 - 
5d - - - - 1.50e+01 - 2.61e+01 - 
5f - - - - 6.86e+00 - 8.78e+00 - 
5g - - - - 1.25e+01 - 1.01e+01 - 
5h - - - - 1.30e+01 - 9.11e+00 - 
5i + - - - 4.52e+00 - 4.10e+00 + 
5j + - - - 8.67e+00 - 7.05e+00 - 
5k + - - - 1.47e+01 - 8.28e+00 - 
5l + - - - 1.37e+01 - 1.03e+01 + 
5q - - - - 1.02e+01 - 3.03e+00 - 
5r - - - - 4.24e+01 - 5.34e+00 - 
5t - - - - 2.16e+02 - 7.31e+00 + 
No risk: (-); Medium risk: (+); High risk: (++) 
EXCLI Journal 2018;17:126-148 – ISSN 1611-2156 
Received: October 10,2017, accepted: January 15, 2018, published: January 19, 2018 
 
 
146 
Acknowledgements 
The authors would like to thank Central 
Drugs Research Institute (CDRI), Lucknow, 
India and Department of Chemistry, 
Banasthali Vidyapith University, Banasthali, 
Rajasthan, India for providing the library and 
sophisticated analytical instrument facilities. 
We would extend our sincere gratitude to the 
All India Council for Technical Education 
(AICTE), New Delhi, India, for providing 
grant under the Research Promotion Scheme 
(Grant No.: 8023/RID/RPS/30 (Pvt.) 2011-
12), through which the computational soft-
ware facility has been made available at the 
host institute and the technical support 
team/application scientists of Schrödinger 
Inc. for their help during implementation of 
the project. 
 
Conflict of interest 
No conflict of interest is reported by the 
authors. 
 
REFERENCES 
Agrawal M, Sonar PK, Saraf SK. Synthesis of 1,3,5-
trisubstituted pyrazoline nucleus containing com-
pounds and screening for antimicrobial activity. Med 
Chem Res. 2012;21:3376-81.  
Amrein R, Martin JR, Cameron AM. Moclobemide in 
patients with dementia and depression. Adv Neurol. 
1999;80:509-19.  
Bhandari S, Tripathi AC, Saraf SK. Synthesis and an-
ticonvulsant activity of some 2-pyrazoline derivatives 
Med Chem Res. 2013;22:5290-6.  
Brown CS, Kent TA, Bryant SG, Gevedon RM, 
Campbell JL, Felthous AR, et al. Blood platelet up-
take of serotonin in episodic aggression. Psychiatry 
Res. 1989; 27:5-12.  
Cesura AM, Pletscher A. The new generation of 
monoamine oxidase inhibitors. Prog Drug Res. 1992; 
38:171-297.  
Chimenti F, Bolasco A, Manna F, Secci D, Chimenti 
P, Befani O, et al. Synthesis and selective inhibitory 
activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-
pyrazole derivatives against monoamine oxidase. J 
Med Chem. 2004;47:2071-4.  
Chimenti F, Carradori S, Secci D, Bolasco A, Bizzarri 
B, Chimenti P, et al. Synthesis and inhibitory activity 
against human monoamine oxidase of N1-thio-
carbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyra-
zole derivatives. Eur J Med Chem. 2010;45:800-4.  
Dhingra D, Goyal PK. The CNS depressant drugs 
such as barbiturates and alcohol reduce the motor ac-
tivity while the stimulants such as caffeine and am-
phetamines increase the activity. Indian J Exp Biol. 
2008;46:212-8.  
Dunham NW, Miya TS. A note on a simple apparatus 
for detecting neurological deficit in rats and mice. J 
Am Pharm Assoc Am Pharm Assoc. 1957;46:208-9. 
Foley P, Gerlach M, Youdim MB, Riederer P. MAO-
B inhibitors: multiple roles in the therapy of neuro-
degenerative disorders? Parkinsonism Relat Disord. 
2000;6:25-47.  
Gareri P, Falconi U, De Fazio P, De Sarro, G. Con-
ventional and new antidepressant drugs in the elderly. 
Prog Neurobiol. 2000;61:353-96.  
Gautam, V, Chawla V, Sonar PK, Saraf SK. Synthe-
ses, characterization and  antimicrobial evaluation of 
Some 1, 3, 5-trisubustituted pyrazole derivatives. E-
Journal of Chemistry. 2010;7:1190-5.  
Gokhan N, Yesilada A, Ucar G, Erol K, Bilgin AA. 1-
N-substituted thiocarbamoyl-3-phenyl-5-thienyl-2-
pyrazolines: synthesis and evaluation as MAO inhibi-
tors. Arch Pharm (Weinheim). 2003;336:362-71.  
Gokhan-Kelekci N, Koyunoglu S, Yabanoglu S, 
Yelekci K, Ozgen O, Ucar G, et al. New pyrazoline 
bearing 4(3H)-quinazolinone inhibitors of monoamine 
oxidase: synthesis, biological evaluation, and struc-
tural determinants of MAO-A and MAO-B selectivi-
ty. Bioorg Med Chem. 2009;7:675-89.  
Jagrat M, Behera J, Yabanoglu S, Ercan A, Ucar G, 
Sinha BN, et al. Pyrazoline based MAO inhibitors: 
Synthesis, biological evaluation and SAR studies. 
Bioorg Med Chem Lett. 2011;21:4296-300.  
Jayaprakash V, Sinha BN, Ucar G, Ercan A. Pyrazo-
line-based mycobactin analogues as MAO-inhibitors. 
Bioorg Med Chem Lett. 2008;18:6362-8.  
Kaplancikli ZA, Ozdemir A, Turan-Zitouni G, Al-
tintop MD, Can OD. New pyrazoline derivatives and 
their antidepressant activity. Eur J Med Chem. 2010; 
45:4383-7.  
Karuppasamy M, Mahapatra M, Yabanoglu S, Ucar 
G, Sinha BN, Basu A, et al. Development of selective 
and reversible pyrazoline based MAO-A inhibitors: 
Synthesis, biological evaluation and docking studies. 
Bioorg Med Chem. 2010;18:1875-81.  
EXCLI Journal 2018;17:126-148 – ISSN 1611-2156 
Received: October 10,2017, accepted: January 15, 2018, published: January 19, 2018 
 
 
147 
Klebe G. Recent developments in structure-based 
drug design. J Mol Med. 2000;78:269–81.  
Lidstrom P, Tierney J, Wathey B, Westman J. Mi-
crowave assisted organic synthesis- a review. Tetra-
hedron. 2001;57:9225-83.  
Lister RG. The use of a plus-maze to measure anxiety 
in the mouse. Psychopharmacology (Berl). 1987;92: 
180-5.  
Maccioni E, Alcaro S, Orallo F, Cardia C, Distinto S, 
Costa G, et al. Synthesis of new 3-aryl-4,5-dihydro-
pyrazole-1-carbothioamide derivatives. An investiga-
tion on their ability to inhibit monoamine oxidase. Eur 
J Med Chem. 2010;45:4490-8.  
Manna F, Chimenti F, Bolasco A, Secci D, Bizzarri 
B, Befani O, et al. Inhibition of amine oxidases activi-
ty by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyra-
zole derivatives. Bioorg Med Chem Lett. 2002;12: 
3629-33.  
Meyer JH, Ginovart N, Boovariwala A, Sagrati S, 
Hussey D, Garcia A, et al. Elevated monoamine oxi-
dase a levels in the brain: an explanation for the mon-
oamine imbalance of major depression. Arch Gen 
Psychiatry. 2006;63:1209-16.  
Mishra N, Sasmal D. Development of selective and 
reversible pyrazoline based MAO-B inhibitors: virtual 
screening, synthesis and biological evaluation. Bioorg 
Med Chem Lett. 2011;21:1969-73.  
Mitoma J, Ito A. Mitochondrial targeting signal of rat 
liver monoamine oxidase B is located at its carboxy 
terminus. J Biochem. 1992;111:20-4.  
OECD Guidelines for Testing of Chemicals 423: 
Acute Oral Toxicity - Acute Toxic Class Method. Par-
is: Organization for Economic Corporation and De-
velopment, 2001.  
Ozdemir Z, Kandilci HB, Gumusel B, Calis U, Bilgin 
AA. Synthesis and studies on antidepressant and anti-
convulsant activities of some 3-(2-thienyl)pyrazoline 
derivatives. Arch Pharm (Weinheim). 2008;341:701-
7.  
Palaska E, Aytemir M, Uzbay IT, Erol D. Synthesis 
and antidepressant activities of some 3,5-diphenyl-2-
pyrazolines. Eur J Med Chem. 2001;36:539-43.  
Pellow S, Chopin P, File SE, Briley M. Validation of 
open:closed arm entries in an elevated plus-maze as a 
measure of anxiety in the rat. J Neurosci Methods. 
1985;14:149-67.  
Pletscher A. The discovery of antidepressants: a 
winding path. Experientia. 1991;47:4-8.  
Porsolt RD. Antidepressants. New York: Raven Press, 
1981.  
Porsolt RD, Bertin A, Jalfre M. Behavioral despair in 
mice: a primary screening test for antidepressants. 
Arch Int Pharmacodyn Ther. 1977;229:327-36.  
Rajendra Prasad Y, Lakshmana Rao A, Prasoona L, 
Murali K, Ravi Kumar P. Synthesis and antidepres-
sant activity of some 1,3,5-triphenyl-2-pyrazolines 
and 3-(2''-hydroxy naphthalen-1''-yl)-1,5-diphenyl-2-
pyrazolines. Bioorg Med Chem Lett. 2005;5:5030-4.  
Ruhoglu O, Ozdemir Z, Calis U, Gumusel B, Bilgin 
AA. Synthesis of and pharmacological studies on the 
antidepressant and anticonvulsant activities of some 
1,3,5-trisubstituted pyrazolines. Arzneimittelfor-
schung. 2005;55:431-6.  
Sahoo A, Yabanoglu S, Sinha BN, Ucar G, Basu A, 
Jayaprakash V. Towards development of selective and 
reversible pyrazoline based MAO-inhibitors: Synthe-
sis, biological evaluation and docking studies. Bioorg 
Med Chem Lett. 2010;20:132-6.  
Steru L, Chermat R, Thierry B, Simon P. The tail sus-
pension test: a new method for screening antidepres-
sants in mice. Psychopharmacology (Berl). 1985;85: 
367-70.  
Parasuraman S. Toxicological screening. J Pharmacol 
Pharmacother. 2011;2:74-9.  
Thase ME. The role of monoamine oxidase inhibitors 
in depression treatment guidelines. J Clin Psychiatry. 
2012;73(Suppl 1):10-6.  
Tripathi AC, Upadhyay S, Paliwal S, Saraf SK. An 
expeditious one-pot microwave facilitated versus 
conventional syntheses: In vivo biological screening 
and molecular docking studies of some 3,5-
disubstituted-4,5-dihydro-(1H)-pyrazole derivatives. 
Med Chem Res. 2016;25:390-406.  
Upadhyay S, Tripathi AC, Paliwal S, Saraf SK. 2-
Pyrazoline derivatives in neuropharmacology: synthe-
sis, ADME prediction, molecular docking and in-vivo 
biological evaluation. EXCLI J. 2017;16:628-49.  
Vogel HG. Drug discovery and evaluation: pharmaco-
logical assays. 2nd ed. Berlin: Springer-Verlag, 2002. 
Volz HP, Gleiter CH. Monoamine oxidase inhibitors. 
A perspective on their use in the elderly. Drugs Ag-
ing. 1998;13:341-55.  
Willner P, Mitchell PJ. The validity of animal models 
of predisposition to depression. Behav Pharmacol. 
2002;13:169-88.  
EXCLI Journal 2018;17:126-148 – ISSN 1611-2156 
Received: October 10,2017, accepted: January 15, 2018, published: January 19, 2018 
 
 
148 
Youdim MB, Edmondson D, Tipton KF. The thera-
peutic potential of monoamine oxidase inhibitors. Nat 
Rev Neurosci. 2006;7:295-309.  
Zeller EA, Barsky J. In vivo inhibition of liver and 
brain monoamine oxidase by 1-Isonicotinyl-2-iso-
propyl hydrazine. Proc Soc Exp Biol Med. 1952; 
81:459-61.  
